<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536833</url>
  </required_header>
  <id_info>
    <org_study_id>SM04690-OA-02</org_study_id>
    <nct_id>NCT02536833</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosplice Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosplice Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety, and tolerability of three&#xD;
      different strengths of SM04690 injected in the target knee joint of moderately to severely&#xD;
      symptomatic osteoarthritis (OA) subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 9, 2015</start_date>
  <completion_date type="Actual">April 20, 2017</completion_date>
  <primary_completion_date type="Actual">April 20, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline Osteoarthritis (OA) Pain in the Target Knee</measure>
    <time_frame>Baseline and Week 13</time_frame>
    <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline OA Pain in the Target Knee</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 26. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline OA Function in the Target Knee</measure>
    <time_frame>Baseline and Week 13</time_frame>
    <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline OA Function in the Target Knee</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 26. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline OA Disease Activity as Assessed by the Patient</measure>
    <time_frame>Baseline and Week 13</time_frame>
    <description>Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 13. The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline OA Disease Activity as Assessed by the Patient</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 26. The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Medial Joint Space Width of Target Knee</measure>
    <time_frame>Baseline and Week 26</time_frame>
    <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 26.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline OA Pain in the Target Knee</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline OA Function in the Target Knee</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Medial Joint Space Width of Target Knee</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline OA Pain in the Target Knee [Unilateral Symptomatic OA]</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline OA Function in the Target Knee [Unilateral Symptomatic OA]</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Medial Joint Space Width of Target Knee [Unilateral Symptomatic OA]</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">455</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>0.03 mg SM04690</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.07 mg SM04690</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.23 mg SM04690</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SM04690</intervention_name>
    <arm_group_label>0.03 mg SM04690</arm_group_label>
    <arm_group_label>0.07 mg SM04690</arm_group_label>
    <arm_group_label>0.23 mg SM04690</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females between 40 and 80 years of age, inclusive, in general good health&#xD;
&#xD;
          2. Ambulatory (single assistive devices such as canes allowed if needed less than 50% of&#xD;
             the time, subjects requiring a walker are excluded)&#xD;
&#xD;
          3. Established diagnosis of primary femorotibial OA in the target knee by standard&#xD;
             American College of Rheumatology (ACR) criteria for at least 6 months (clinical AND&#xD;
             radiographic criteria); if bilateral knee OA is present, the target knee is defined as&#xD;
             the knee with greater pain at screening based on the subject's evaluation and the&#xD;
             Investigator's clinical judgment&#xD;
&#xD;
          4. Radiographic disease Stage 2 or 3 in the target knee according to the&#xD;
             Kellgren-Lawrence grading of knee OA as assessed by independent central readers&#xD;
&#xD;
          5. Screening pain visual analog scale (VAS) score of 30-80 mm (on a scale of 0-100 mm)&#xD;
             for the target knee while on symptomatic oral treatment at screening (if the subject&#xD;
             requires oral treatment)&#xD;
&#xD;
          6. Total WOMAC score of 72-192 (out of 240) for the target knee while on symptomatic oral&#xD;
             treatment at screening (if the subject requires oral treatment)&#xD;
&#xD;
          7. Willingness to omit the following for 24 hours prior to all Study Visits, excluding&#xD;
             the Screening Visit:&#xD;
&#xD;
               1. Pain medications&#xD;
&#xD;
               2. Medications or supplements for the treatment of OA&#xD;
&#xD;
               3. Participation in a formalized in-office and/or supervised OA disease program&#xD;
                  (e.g., a prescribed patient education program, physiotherapy, etc.)&#xD;
&#xD;
          8. Full understanding of the requirements of the study and willingness to comply with all&#xD;
             study visits and assessments&#xD;
&#xD;
          9. Subjects must have read and understood the informed consent form, and must have signed&#xD;
             it prior to any study-related procedure being performed&#xD;
&#xD;
         10. Subject's Day 1 visit must occur while enrollment into the study is open&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Women who are pregnant or lactating&#xD;
&#xD;
          2. Women of childbearing potential (i.e., who are not surgically sterile or&#xD;
             postmenopausal as defined by no menstrual periods for 12 consecutive months and no&#xD;
             other biological or physiological cause for amenorrhea can be identified); males who&#xD;
             are sexually active and have a partner who is capable of becoming pregnant, neither of&#xD;
             which have had surgery to become sterilized, who are not using an effective method of&#xD;
             birth control (e.g., surgically-implanted hormonal therapy, intrauterine devices or&#xD;
             oral birth control with barrier method)&#xD;
&#xD;
          3. Body mass index (BMI) &gt;40&#xD;
&#xD;
          4. Partial or complete joint replacement in the target knee&#xD;
&#xD;
          5. Previous exposure to SM04690&#xD;
&#xD;
          6. Major surgery (e.g., interventional arthroscopy) in the target knee within 52 weeks&#xD;
             prior to any study injection&#xD;
&#xD;
          7. Any planned or elective surgery during the study period&#xD;
&#xD;
          8. Significant and clinically evident misalignment of the target knee that would impact&#xD;
             subject function, as determined by the Investigator&#xD;
&#xD;
          9. History of malignancy within the last 5 years; however, subjects with prior history of&#xD;
             in situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other&#xD;
             malignancies are eligible if they have been continuously disease free for at least 5&#xD;
             years prior to any study injection&#xD;
&#xD;
         10. Clinically significant abnormal Screening Visit hematology values, blood chemistry&#xD;
             values, HbA1c, or urinalysis values as determined by the investigator&#xD;
&#xD;
         11. Any condition, including laboratory findings (not included in the Screening Visit&#xD;
             laboratory tests) and findings in the medical history or in the pre-study assessments,&#xD;
             that, in the opinion of the Investigator, constitutes a risk or contraindication for&#xD;
             participation in the study or that could interfere with the study objectives, conduct,&#xD;
             or evaluation&#xD;
&#xD;
         12. Comorbid conditions that could affect pain assessment of the target knee, including,&#xD;
             but not limited to, inflammatory rheumatic conditions such as rheumatoid arthritis,&#xD;
             psoriatic arthritis, systemic lupus erythematosus, diabetic neuropathy, pseudogout,&#xD;
             gout, and fibromyalgia&#xD;
&#xD;
         13. Other conditions that, in the opinion of the Investigator, could affect pain&#xD;
             assessment of the target knee, including, but not limited to, symptomatic hip&#xD;
             osteoarthritis and symptomatic degenerative disc disease&#xD;
&#xD;
         14. Any diagnosed psychiatric condition that includes, but is not limited to, a history of&#xD;
             mania, bipolar disorder, psychotic disorder, schizophrenia, major depressive disorder,&#xD;
             or generalized anxiety disorder&#xD;
&#xD;
         15. Participation in a clinical research trial that included the receipt of an&#xD;
             investigational product or any experimental therapeutic procedure within 12 weeks&#xD;
             prior to any study injection; the last date of participation in the trial, not the&#xD;
             last date of receipt of investigational product, must be at least 12 weeks prior to&#xD;
             Study Visit Day 1&#xD;
&#xD;
         16. Treatment of the target knee with systemic or intra-articular corticosteroids (e.g.,&#xD;
             methylprednisolone) within 8 weeks prior to Study Visit Day 1&#xD;
&#xD;
         17. Viscosupplementation (e.g., hyaluronic acid) in the target knee within 24 weeks prior&#xD;
             to Study Visit Day 1&#xD;
&#xD;
         18. Effusion of the target knee clinically requiring aspiration within 12 weeks prior to&#xD;
             Study Visit Day 1&#xD;
&#xD;
         19. Use of electrotherapy, acupuncture, and/or chiropractic treatments for knee OA within&#xD;
             4 weeks prior to Study Visit Day 1&#xD;
&#xD;
         20. Any known active infections, including suspicion of intra-articular infection,&#xD;
             hepatitis B or hepatitis C infection, and/or infections that may compromise the immune&#xD;
             system such as human immunodeficiency virus (HIV)&#xD;
&#xD;
         21. Subjects taking prescription medications for OA who have not maintained a stable&#xD;
             therapeutic regimen for a minimum of 12 weeks prior to Study Visit Day 1&#xD;
&#xD;
         22. Subjects requiring the chronic use (i.e., regular and consistent use for ≥ 12 weeks)&#xD;
             of the medications listed below within 12 weeks prior to Study Visit Day 1:&#xD;
&#xD;
               1. Opioids, both oral (e.g., tramadol) or transdermal (e.g., fentanyl patches)&#xD;
                  formulations&#xD;
&#xD;
               2. Centrally acting analgesics (e.g., duloxetine)&#xD;
&#xD;
               3. Glucocorticoids (e.g., methylprednisolone) administered by any route, with&#xD;
                  exception of inhaled, intranasal, and ophthalmic solutions&#xD;
&#xD;
         23. Any chronic condition that has not been well controlled or subjects with a chronic&#xD;
             condition who have not maintained a stable therapeutic regimen of a prescription&#xD;
             therapy for a minimum of 12 weeks prior to Study Visit Day 1. In addition, the&#xD;
             following subjects will be excluded:&#xD;
&#xD;
               1. Subjects with a baseline HbA1c &gt;9&#xD;
&#xD;
               2. Subjects with uncontrolled hypertension in the opinion of the investigator&#xD;
&#xD;
               3. Subjects with symptomatic coronary artery disease in the opinion of the&#xD;
                  investigator&#xD;
&#xD;
         24. Subjects who have a current or pending disability claim, workers' compensation, or&#xD;
             litigation(s) that may compromise response to treatment&#xD;
&#xD;
         25. Subjects who are immediate family members (spouse, parent, child, or sibling;&#xD;
             biological or legally adopted) of personnel directly affiliated with the study at the&#xD;
             investigative site, or are directly affiliated with the study at the investigative&#xD;
             site&#xD;
&#xD;
         26. Subjects employed by Samumed, LLC, or any of its affiliates or development partners&#xD;
             (that is, an employee, temporary contract worker, or designee) responsible for the&#xD;
             conduct of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yusuf Yazici, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Biosplice Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodstock</city>
        <state>Georgia</state>
        <zip>30189</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 1</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site 2</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Orchard Park</city>
        <state>New York</state>
        <zip>14127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Franklin</city>
        <state>Wisconsin</state>
        <zip>53132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Yazici Y, McAlindon TE, Gibofsky A, Lane NE, Clauw D, Jones M, Bergfeld J, Swearingen CJ, DiFrancesco A, Simsek I, Tambiah J, Hochberg MC. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial. Arthritis Rheumatol. 2020 Oct;72(10):1694-1706. doi: 10.1002/art.41315. Epub 2020 Sep 6.</citation>
    <PMID>32432388</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <results_first_submitted>July 23, 2020</results_first_submitted>
  <results_first_submitted_qc>August 26, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2020</results_first_posted>
  <disposition_first_submitted>July 24, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>July 24, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">July 26, 2018</disposition_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Samumed</keyword>
  <keyword>SM04690</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lorecivivint</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 13, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02536833/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02536833/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>0.03 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="P2">
          <title>0.07 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="P3">
          <title>0.23 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="110"/>
                <participants group_id="P4" count="116"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="107"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued Before Treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Analysis Population is the Intent-to-Treat (ITT) Analysis Set (i.e. all participants who were randomized).</population>
      <group_list>
        <group group_id="B1">
          <title>0.03 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="B2">
          <title>0.07 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="B3">
          <title>0.23 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
            <count group_id="B2" value="117"/>
            <count group_id="B3" value="110"/>
            <count group_id="B4" value="116"/>
            <count group_id="B5" value="455"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="9"/>
                    <measurement group_id="B2" value="60" spread="8.2"/>
                    <measurement group_id="B3" value="61.3" spread="8.7"/>
                    <measurement group_id="B4" value="60.7" spread="8.9"/>
                    <measurement group_id="B5" value="60.3" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="268"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="93"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="374"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="102"/>
                    <measurement group_id="B5" value="392"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kellgren-Lawrence Grade</title>
          <description>Participants' knee osteoarthritis was graded in accordance with the following definitions of Kellgren-Lawrence Grade: None (Grade 0) - Normal appearance of the knee; Doubtful (Grade 1): Doubtful narrowing of joint space and possible osteophytic lipping; Minimal (Grade 2): Definite osteophytes and possible narrowing of joint space; Moderate (Grade 3): Moderate multiple osteophytes, definite narrowing of the joint space, some sclerosis and possible deformity of bone ends; Severe (Grade 4): Large osteophytes, marked narrowing of joint space, severe sclerosis and definite deformity of bone ends.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="39"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="70"/>
                    <measurement group_id="B4" value="74"/>
                    <measurement group_id="B5" value="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline Osteoarthritis (OA) Pain in the Target Knee</title>
        <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
        <time_frame>Baseline and Week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Osteoarthritis (OA) Pain in the Target Knee</title>
          <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.3" spread="2.2"/>
                    <measurement group_id="O2" value="-23.5" spread="2.1"/>
                    <measurement group_id="O3" value="-21.3" spread="2.2"/>
                    <measurement group_id="O4" value="-22.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.575</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.57</ci_lower_limit>
            <ci_upper_limit>3.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.643</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.63</ci_lower_limit>
            <ci_upper_limit>4.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.901</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.07</ci_lower_limit>
            <ci_upper_limit>5.75</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline OA Pain in the Target Knee</title>
        <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 26. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Pain in the Target Knee</title>
          <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 26. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="2.3"/>
                    <measurement group_id="O2" value="-27.3" spread="2.0"/>
                    <measurement group_id="O3" value="-23.3" spread="2.1"/>
                    <measurement group_id="O4" value="-24.4" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.271</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.31</ci_lower_limit>
            <ci_upper_limit>2.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.898</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.06</ci_lower_limit>
            <ci_upper_limit>5.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.795</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.74</ci_lower_limit>
            <ci_upper_limit>6.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline OA Function in the Target Knee</title>
        <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
        <time_frame>Baseline and Week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Function in the Target Knee</title>
          <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 13. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.5" spread="2.1"/>
                    <measurement group_id="O2" value="-26.3" spread="2.0"/>
                    <measurement group_id="O3" value="-22.6" spread="2.1"/>
                    <measurement group_id="O4" value="-22.8" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.283</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.74</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.588</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.82</ci_lower_limit>
            <ci_upper_limit>3.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.853</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.76</ci_lower_limit>
            <ci_upper_limit>4.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline OA Function in the Target Knee</title>
        <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 26. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Function in the Target Knee</title>
          <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 26. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.1" spread="2.2"/>
                    <measurement group_id="O2" value="-28.6" spread="2.0"/>
                    <measurement group_id="O3" value="-24.1" spread="2.0"/>
                    <measurement group_id="O4" value="-25.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.292</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.26</ci_lower_limit>
            <ci_upper_limit>2.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.931</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.34</ci_lower_limit>
            <ci_upper_limit>5.83</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.878</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.92</ci_lower_limit>
            <ci_upper_limit>5.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline OA Disease Activity as Assessed by the Patient</title>
        <description>Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 13. The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
        <time_frame>Baseline and Week 13</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Disease Activity as Assessed by the Patient</title>
          <description>Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 13. The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.1" spread="2.3"/>
                    <measurement group_id="O2" value="-13.7" spread="2.3"/>
                    <measurement group_id="O3" value="-14.6" spread="2.6"/>
                    <measurement group_id="O4" value="-14.0" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.648</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.83</ci_lower_limit>
            <ci_upper_limit>6.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.209</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.02</ci_lower_limit>
            <ci_upper_limit>1.75</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.915</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.78</ci_lower_limit>
            <ci_upper_limit>5.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline OA Disease Activity as Assessed by the Patient</title>
        <description>Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 26. The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Disease Activity as Assessed by the Patient</title>
          <description>Change from baseline OA disease activity as assessed by the Patient Global Assessment at Week 26. The Patient Global Assessment was completed using a 100 mm visual analog scale (VAS) adapted from the Patient Assessment Form © 1999, American College of Rheumatology. The subject rated how well he/she was doing, considering all the ways in which illness and health conditions may affected him/her. The VAS scale was anchored by &quot;Very Well&quot; on the left (scored as 0) and &quot;Very Poorly&quot; on the right (scored as 100). Higher scores indicated poorer disease assessment by the subject.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.3" spread="2.4"/>
                    <measurement group_id="O2" value="-17.5" spread="2.3"/>
                    <measurement group_id="O3" value="-17.2" spread="2.6"/>
                    <measurement group_id="O4" value="-16.6" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.969</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.16</ci_lower_limit>
            <ci_upper_limit>5.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.174</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.89</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.908</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.97</ci_lower_limit>
            <ci_upper_limit>5.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Medial Joint Space Width of Target Knee</title>
        <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 26.</description>
        <time_frame>Baseline and Week 26</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medial Joint Space Width of Target Knee</title>
          <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 26.</description>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.06"/>
                    <measurement group_id="O2" value="-0.11" spread="0.08"/>
                    <measurement group_id="O3" value="-0.02" spread="0.06"/>
                    <measurement group_id="O4" value="-0.20" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.334</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.124</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.032</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline OA Pain in the Target Knee</title>
        <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Pain in the Target Knee</title>
          <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.7" spread="2.5"/>
                    <measurement group_id="O2" value="-29.0" spread="2.1"/>
                    <measurement group_id="O3" value="-25.5" spread="2.1"/>
                    <measurement group_id="O4" value="-26.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.405</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.00</ci_lower_limit>
            <ci_upper_limit>3.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.552</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.37</ci_lower_limit>
            <ci_upper_limit>8.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.763</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.91</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline OA Function in the Target Knee</title>
        <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Function in the Target Knee</title>
          <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.1" spread="2.5"/>
                    <measurement group_id="O2" value="-29.6" spread="2.0"/>
                    <measurement group_id="O3" value="-24.9" spread="2.1"/>
                    <measurement group_id="O4" value="-25.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.173</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.50</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.724</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.12</ci_lower_limit>
            <ci_upper_limit>7.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.914</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.17</ci_lower_limit>
            <ci_upper_limit>5.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Medial Joint Space Width of Target Knee</title>
        <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medial Joint Space Width of Target Knee</title>
          <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.</description>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="110"/>
                <count group_id="O4" value="116"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.06"/>
                    <measurement group_id="O2" value="-0.09" spread="0.06"/>
                    <measurement group_id="O3" value="-0.16" spread="0.07"/>
                    <measurement group_id="O4" value="-0.14" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.529</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.259</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.08</ci_lower_limit>
            <ci_upper_limit>0.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.807</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline OA Pain in the Target Knee [Unilateral Symptomatic OA]</title>
        <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Subjects with unilateral symptomatic OA in the ITT Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Pain in the Target Knee [Unilateral Symptomatic OA]</title>
          <description>Change from baseline OA pain in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) pain subscore (WOMAC Pain) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Pain subscore is reported ranging from 0 to 100.</description>
          <population>Subjects with unilateral symptomatic OA in the ITT Analysis Set.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="3.5"/>
                    <measurement group_id="O2" value="-30.1" spread="3.2"/>
                    <measurement group_id="O3" value="-26.6" spread="3.1"/>
                    <measurement group_id="O4" value="-23.8" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.44</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.211</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.49</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.254</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.23</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.24</ci_lower_limit>
            <ci_upper_limit>3.78</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline OA Function in the Target Knee [Unilateral Symptomatic OA]</title>
        <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Subjects with unilateral symptomatic OA in the ITT Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline OA Function in the Target Knee [Unilateral Symptomatic OA]</title>
          <description>Change from baseline OA function in the target knee as assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Numeric Rating Scale (NRS 3.1) physical functioning subscore (WOMAC Function) at Week 52. The WOMAC is a widely-used, proprietary outcome measurement tool used by health professionals to evaluate the condition of subjects with OA of the knee and hip, including pain (5 questions), stiffness (2 questions), and physical functioning (17 questions) of the joints. Each question is measured on a scale from 0 (lowest pain/lowest stiffness/highest function) to 10 (highest pain/highest stiffness/lowest function). The WOMAC Function subscore is reported ranging from 0 to 100.</description>
          <population>Subjects with unilateral symptomatic OA in the ITT Analysis Set.</population>
          <units>score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.0" spread="3.9"/>
                    <measurement group_id="O2" value="-29.9" spread="3.4"/>
                    <measurement group_id="O3" value="-25.6" spread="3.1"/>
                    <measurement group_id="O4" value="-21.5" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.036</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-10.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.82</ci_lower_limit>
            <ci_upper_limit>-0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.170</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.18</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.171</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.33</ci_lower_limit>
            <ci_upper_limit>2.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Medial Joint Space Width of Target Knee [Unilateral Symptomatic OA]</title>
        <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>Subjects with unilateral symptomatic OA in the ITT Analysis Set.</population>
        <group_list>
          <group group_id="O1">
            <title>0.03 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O2">
            <title>0.07 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O3">
            <title>0.23 mg SM04690</title>
            <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Medial Joint Space Width of Target Knee [Unilateral Symptomatic OA]</title>
          <description>Change from baseline in medial joint space width as documented by X-ray of the target knee at Week 52.</description>
          <population>Subjects with unilateral symptomatic OA in the ITT Analysis Set.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="45"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.10"/>
                    <measurement group_id="O2" value="0.19" spread="0.12"/>
                    <measurement group_id="O3" value="-0.22" spread="0.11"/>
                    <measurement group_id="O4" value="-0.21" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.021</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.06</ci_lower_limit>
            <ci_upper_limit>0.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.131</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.789</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Data regarding treatment-emergent adverse events (TEAEs) was collected in this study. TEAEs are events that were not present prior to study medication injection or, if present prior to study medication injection, had worsened in severity. The reporting period for TEAEs started after the injection of study medication on Study Visit Day 1 through Week 52 (End of Study)/Early Termination.</time_frame>
      <desc>Safety Analyses Set: All participants who were exposed to SM04690 or placebo. Safety was assessed using the actual treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>0.03 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.03 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="E2">
          <title>0.07 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.07 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="E3">
          <title>0.23 mg SM04690</title>
          <description>Single intra-articular injection of SM04690 0.23 mg in 2 mL injectable suspension</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Single intra-articular injection of SM04690 0 mg in 2 mL phosphate buffered saline</description>
        </group>
        <group group_id="E5">
          <title>Other</title>
          <description>Single intra-articular injection of an unidentified dose of SM04690 or Placebo due to incorrectly performed dilution or documentation by a pharmacist.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Gallbladder adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="104"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="108"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oesophageal motility disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="114"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="104"/>
                <counts group_id="E4" events="12" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Joint crepitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Patellofemoral pain syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased vibratory sense</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="104"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="104"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christopher Swearingen, PhD, VP of Clinical Outcomes and Analytics</name_or_title>
      <organization>Samumed</organization>
      <phone>858.926.2952</phone>
      <email>chris@samumed.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

